-
1 Comment
GeneOne Life Science, Inc is currently in a long term uptrend where the price is trading 131.1% above its 200 day moving average.
From a valuation standpoint, the stock is 40.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 12.0.
GeneOne Life Science, Inc's total revenue sank by 3.5% to $12B since the same quarter in the previous year.
Its net income has dropped by 242.6% to $-10B since the same quarter in the previous year.
Finally, its free cash flow fell by 194.2% to $-15B since the same quarter in the previous year.
Based on the above factors, GeneOne Life Science, Inc gets an overall score of 1/5.
| Sector | Healthcare |
|---|---|
| CurrencyCode | KRW |
| Exchange | KO |
| ISIN | KR7011000007 |
| Industry | Biotechnology |
| Market Cap | 544B |
|---|---|
| PE Ratio | None |
| Dividend Yield | 0.0% |
| Beta | -1.63 |
| Target Price | None |
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the development and contract manufacturing of gene-based-biomedicines. Its products comprise GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company also develops GLS-3000 and GLS-5310 for the treatment of SARS-CoV-2; GLS-5100 to treat VZV-Shingles; and GLS-5140 for the treatment of SFTS. In addition, it is developing GLS-5300, which is in Phase II clinical trial for MERS; GLS-5700 that is in Phase I clinical trial for Zika; and GLS-6150, which is in Phase I clinical trial for treatment of hepatitis C, as well as GLS-6100 that is in pre-clinical stage for hepatitis C. Further, the company, through its subsidiary, VGXI, Inc., engages in the cGMP production of nucleic acid-based products, including DNA plasmids and mRNA. The company was formerly known as VGX International Inc. and changed its name to GeneOne Life Science, Inc. in April 2014. GeneOne Life Science, Inc. was founded in 1976 and is headquartered in Seoul, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 011000.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
